Research programme: antifibrinolytic therapeutics - Edge Therapeutics

Drug Profile

Research programme: antifibrinolytic therapeutics - Edge Therapeutics

Alternative Names: EG-1963

Latest Information Update: 22 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Edge Therapeutics
  • Class
  • Mechanism of Action Antifibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Surgical blood loss

Most Recent Events

  • 22 Dec 2015 Early research in Surgical blood loss in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top